Shanghai CataX Biopharmaceutical Technology Co., Ltd. (CataX AI) has recently completed a 40 million RMB seed round financing, incubated and exclusively invested by Qiming Venture Partners. Founded in Shanghai, CataX AI is an innovative drug R&D company built on an Agent-based technology foundation. The company focuses on the clinical development end and is building a 'Clinical-of-One' (full-stack clinical) organizational paradigm. It plans to advance preclinical and early-clinical-stage assets to complete clinical proof of concept (PoC) through licensing-in or co-development.
